Evidence map›Paper›PMID 41545352›Full record

ArticleBone research2026

APEX1, a transcriptional hub for endochondral ossification and fracture repair.

José Valdés-Fernández, Miguel Echanove-González de Anleo, Juan Antonio Romero-Torrecilla, Tania López-Martínez, Purificación Ripalda-Cemboráin, María Erendira Calleja-Cervantes, Asier Ullate-Agote, Elena Iglesias, Belén Prados-Pinto, José Luis de la Pompa and 3 more

Abstract read
In one paragraph

Article in Bone research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

José Valdés-FernándezCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
Miguel Echanove-González de AnleoCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
Juan Antonio Romero-TorrecillaCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
Tania López-MartínezCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-0879-3995
Purificación Ripalda-CemboráinCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0001-8425-3563
María Erendira Calleja-CervantesHemato-Oncology Program, Centre for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.ORCID 0000-0003-0688-0793
Asier Ullate-AgoteInstituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.ORCID 0000-0002-8595-7703
Elena IglesiasBiomedical Engineering Program, Centre for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Belén Prados-PintoIntercellular Signaling in Cardiovascular Development and Disease Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
José Luis de la PompaIntercellular Signaling in Cardiovascular Development and Disease Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Felipe PrósperCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0001-6115-8790
Emma Muiños-LópezCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain. emuinos@unav.es.ORCID 0000-0002-6618-4135
Froilán Granero-MoltóCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0003-4817-5232

Funding

"la Caixa" Foundation (Caixa Foundation) Ref. HR23-00084Universidad de Navarra (University of Navarra) Asociación de Amigos de la Universidad de Navarra
6 · The paper itself

Abstract

After injury, bone tissue initiates a reparative response to restore its structure and function. The failure to initiate or delay this response could result in fracture nonunion. The molecular mechanisms underlying the occurrence of fracture nonunion are not yet established. We propose that hypoxia-triggered signaling pathways, mediated by reactive oxygen species (ROS) homeostasis, control Bmp2 expression and fracture healing initiation. The excessive ROS leads to oxidative stress and, ultimately, fracture nonunion. In this study, we silenced Apex1, the final ROS signaling transducer that mediates the activation of key transcription factors by their cysteines oxidoreduction, evaluating its role during endochondral ossification and fracture repair. Silencing Apex1 in limb bud mesenchyme results in transient metaphyseal dysplasia derived from impaired chondrocyte differentiation. During bone regeneration, Apex1 silencing induces a fracture nonunion phenotype, characterized by delayed fracture repair initiation, impaired periosteal response, and reduced chondrocyte and osteoblast differentiation. This compromised chondrocyte differentiation hampers callus vascularization and healing progression. Our findings highlight a critical mechanism where hypoxia-driven ROS signaling in mesenchymal progenitors through APEX1 is essential for fracture healing initiation.

Indexed as

DNA-(Apurinic or Apyrimidinic Site) LyaseFracture HealingFractures, BoneOsteogenesisTranscription, GeneticAnimalsCell DifferentiationChondrocytesHumansMiceOsteoblastsReactive Oxygen SpeciesSignal TransductionApex1 protein, mouseDNA-(Apurinic or Apyrimidinic Site) LyaseReactive Oxygen Species

Identifiers

PMID41545352
PMCPMC12811256

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.